HER2阳性、低级别、无淋巴结转移的乳腺癌患者生存结局较差。
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.
作者信息
Tovey S M, Brown S, Doughty J C, Mallon E A, Cooke T G, Edwards J
机构信息
Glasgow Royal Infirmary, Section of Surgery, Division of Cancer Sciences and Molecular Pathology, Faculty of Medicine, UK.
出版信息
Br J Cancer. 2009 Mar 10;100(5):680-3. doi: 10.1038/sj.bjc.6604940. Epub 2009 Feb 17.
Abstract
We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support for the use of adjuvant trastuzumab in patients who are typically classified as having very good prognosis, not routinely offered standard chemotherapy, and who as such do not fit current UK prescribing guidelines for trastuzumab.
摘要
我们对一组低级别、无淋巴结转移的患者进行了回顾性分析，结果显示，人表皮生长因子受体2（HER2）状态显著影响这一预后通常非常良好的患者群体的生存情况。我们的研究结果支持在那些通常被归类为预后非常良好、未常规接受标准化化疗且不符合英国目前曲妥珠单抗处方指南的患者中使用辅助性曲妥珠单抗。
相似文献
1
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.
Br J Cancer. 2009 Mar 10;100(5):680-3. doi: 10.1038/sj.bjc.6604940. Epub 2009 Feb 17.
2
Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.
3
Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
Asian Pac J Cancer Prev. 2015;16(4):1643-9. doi: 10.7314/apjcp.2015.16.4.1643.
4
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Oncotarget. 2016 Aug 30;7(35):56295-56308. doi: 10.18632/oncotarget.10787.
5
HER2 as a prognostic factor in breast cancer.
Oncology. 2001;61 Suppl 2:67-72. doi: 10.1159/000055404.
6
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Clin Transl Oncol. 2008 Oct;10(10):646-53. doi: 10.1007/s12094-008-0265-y.
7
Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
BMC Cancer. 2017 Dec 28;17(1):895. doi: 10.1186/s12885-017-3897-x.
8
Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
Anticancer Res. 2018 Apr;38(4):2109-2117. doi: 10.21873/anticanres.12451.
9
Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status.
Eur J Cancer Care (Engl). 2015 Nov;24(6):920-8. doi: 10.1111/ecc.12306. Epub 2015 Mar 10.
10
The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Breast Cancer. 2021 Jan;28(1):187-195. doi: 10.1007/s12282-020-01146-4. Epub 2020 Aug 18.
引用本文的文献
1
The characteristics of HER2-positive microinvasive breast cancer and the necessity of systemic adjuvant therapy in these patients: a multicenter real-world study.
Ther Adv Med Oncol. 2025 Jun 16;17:17588359251345716. doi: 10.1177/17588359251345716. eCollection 2025.
2
Vaccines for cancer prevention: exploring opportunities and navigating challenges.
Nat Rev Drug Discov. 2025 Feb;24(2):134-150. doi: 10.1038/s41573-024-01081-5. Epub 2024 Dec 2.
3
The dynamics of HER2-low expression during breast cancer progression.
Breast Cancer Res Treat. 2023 Oct;201(3):437-446. doi: 10.1007/s10549-023-07020-z. Epub 2023 Jul 12.
4
Aspects of Phage-Based Vaccines for Protein and Epitope Immunization.
Vaccines (Basel). 2023 Feb 14;11(2):436. doi: 10.3390/vaccines11020436.
5
Mining TCGA Database for Genes with Prognostic Value in Breast Cancer.
Int J Mol Sci. 2023 Jan 13;24(2):1622. doi: 10.3390/ijms24021622.
6
Transcriptomic profiling of Indian breast cancer patients revealed subtype-specific mRNA and lncRNA signatures.
Front Genet. 2022 Oct 25;13:932060. doi: 10.3389/fgene.2022.932060. eCollection 2022.
7
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies.
Target Oncol. 2022 Nov;17(6):655-663. doi: 10.1007/s11523-022-00923-9. Epub 2022 Nov 7.
8
Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.
Front Immunol. 2021 Nov 24;12:786286. doi: 10.3389/fimmu.2021.786286. eCollection 2021.
9
Long-term oncologic outcomes of breast conserving surgery with propofol-based total intravenous anesthesia or volatile inhalational general anesthesia without propofol: a propensity score-matched, population-based cohort study.
Am J Cancer Res. 2021 Oct 15;11(10):4966-4980. eCollection 2021.
10
Differentiation and Regulation of T Cells: A Balancing Act for Cancer Immunotherapy.
Front Immunol. 2021 May 3;12:669474. doi: 10.3389/fimmu.2021.669474. eCollection 2021.
本文引用的文献
1
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
J Clin Oncol. 2008 Dec 10;26(35):5697-704. doi: 10.1200/JCO.2007.15.8659. Epub 2008 Nov 10.
2
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
Ann Oncol. 2008 Jun;19(6):1090-6. doi: 10.1093/annonc/mdn005. Epub 2008 Feb 21.
3
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Lancet Oncol. 2008 Jan;9(1):23-8. doi: 10.1016/S1470-2045(07)70386-8. Epub 2007 Dec 20.
4
The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study.
Int J Surg Pathol. 2007 Apr;15(2):98-109. doi: 10.1177/1066896906299124.
5
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Lancet. 2007 Jan 6;369(9555):29-36. doi: 10.1016/S0140-6736(07)60028-2.
6
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
N Engl J Med. 2005 Oct 20;353(16):1673-84. doi: 10.1056/NEJMoa052122.
7
Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
Breast Cancer Res. 2005;7(2):R256-66. doi: 10.1186/bcr991. Epub 2005 Jan 26.
8
The clinical evaluation of HER-2 status: which test to use?
J Pathol. 2003 Apr;199(4):411-7. doi: 10.1002/path.1354.
9
10
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
Int J Oncol. 1999 Apr;14(4):663-71. doi: 10.3892/ijo.14.4.663.
Zotero 插件